Tres Alchemix Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $4.4M

  • Investors
  • 2

Tres Alchemix General Information

Description

Developer of an AI-powered biotechnology platform designed to build human in silico models that can predict the efficacy and safety of new compounds. The company's platform integrates multimodal and multi-omics data with proprietary quantum chemistry calculations to predict drug pharmacokinetics and pharmacodynamics and analyze how chemicals behave within cells, tissues, and the human body, enabling clients to make the complexity of the human body interpretable.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 312, Tokan Hakata, 5th Building
  • 2-19-17 Hakata Ekimae, Hakata-ku
  • Fukuoka
  • Japan
+81
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • Room 312, Tokan Hakata, 5th Building
  • 2-19-17 Hakata Ekimae, Hakata-ku
  • Fukuoka
  • Japan
+81

Tres Alchemix Timeline

202420252026
Date FoundedFinancing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tres Alchemix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 26-Sep-2025 $4.4M Completed Generating Revenue
1. Seed Round 16-Aug-2023 Completed Generating Revenue
To view Tres Alchemix’s complete valuation and funding history, request access »

Tres Alchemix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Start-up investment stock
To view Tres Alchemix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Tres Alchemix Patents

Tres Alchemix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025197052-A1 Molecule analysis system, program, and molecule analysis method Pending 22-Mar-2024
EP-4629144-A1 Prediction device, prediction method, and prediction program Pending 30-Nov-2022
EP-4629144-A4 Prediction device, prediction method, and prediction program Pending 30-Nov-2022
JP-2025134955-A Prediction device, prediction method, and prediction program Pending 30-Nov-2022
JP-7706817-B2 Prediction device, prediction method, and prediction program Active 30-Nov-2022 G06N20/00
To view Tres Alchemix’s complete patent history, request access »

Tres Alchemix Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
DNX Ventures Venture Capital Minority
Waseda University Ventures Venture Capital Minority
To view Tres Alchemix’s complete investors history, request access »

Tres Alchemix FAQs

  • When was Tres Alchemix founded?

    Tres Alchemix was founded in 2023.

  • Where is Tres Alchemix headquartered?

    Tres Alchemix is headquartered in Fukuoka, Japan.

  • What industry is Tres Alchemix in?

    Tres Alchemix’s primary industry is Biotechnology.

  • Is Tres Alchemix a private or public company?

    Tres Alchemix is a Private company.

  • What is the current valuation of Tres Alchemix?

    The current valuation of Tres Alchemix is .

  • What is Tres Alchemix’s current revenue?

    The current revenue for Tres Alchemix is .

  • How much funding has Tres Alchemix raised over time?

    Tres Alchemix has raised $5.8M.

  • Who are Tres Alchemix’s investors?

    DNX Ventures and Waseda University Ventures have invested in Tres Alchemix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process